Retatrutide is injected into the subcutaneous fat layer — the tissue just beneath the skin — making it consistent with other injectable medicines in the incretin-based therapy class. As an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, retatrutide is currently undergoing Phase 3 clinical trials for obesity and type 2 diabetes. It is not yet approved for use in the UK. This article explains what subcutaneous injection means in practice, how to choose and rotate injection sites, correct technique, and what side effects to watch for — alongside the current regulatory status of retatrutide in the United Kingdom.

How and Where Retatrutide Is Injected

Retatrutide is administered via subcutaneous injection into the fatty tissue layer beneath the skin, studied as a once-weekly injection consistent with other incretin-based therapies such as semaglutide and tirzepatide.

Retatrutide is an investigational injectable medicine currently undergoing clinical evaluation for the treatment of obesity and type 2 diabetes. It belongs to a novel class of agents known as triple agonists, targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously. Based on its mechanism of action, this multi-receptor approach is hypothesised to reduce appetite, support glucose regulation, and increase energy expenditure — though these effects remain under investigation and have not yet been confirmed through completed Phase 3 trials.

Like other medicines in the incretin-based therapy class — such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) — retatrutide is administered via subcutaneous injection. This means it is injected beneath the skin, into the layer of fatty (adipose) tissue that lies just below the dermis. So, to answer the question directly: yes, retatrutide is injected into fat — specifically, the subcutaneous fat layer.

Most peptide-based medicines are not orally bioavailable, as digestive enzymes would break them down before they reach the bloodstream (though exceptions exist, such as oral semaglutide). Retatrutide is currently being studied as a once-weekly subcutaneous injection, a route that allows the drug to be absorbed gradually and reliably into systemic circulation. This dosing schedule and route are consistent with data from the Phase 2 trial published in the New England Journal of Medicine (2023); the current development phase and trial details can be verified via ClinicalTrials.gov. Please note that information about the specific delivery device used in trials has not been confirmed in publicly available sources and is therefore not described here.

Subcutaneous Injection: What This Means for Patients

Subcutaneous injection delivers medication into the hypodermis — the fatty layer between skin and muscle — allowing slower, consistent absorption; retatrutide is only available within approved clinical trials in the UK.

Subcutaneous (SC) injection involves delivering medication into the hypodermis — the layer of loose connective and fatty tissue situated between the skin and the underlying muscle. This tissue is vascularised but less densely so than muscle, which means absorption is slower and more consistent, making it well suited to medicines intended to act over an extended period.^[6][7]

It is important to note that retatrutide is currently only available within approved clinical trials, where participants receive training from the research team before self-administering. Outside of a trial setting, retatrutide is not available for use in the UK.

For subcutaneous injections in general, the method is well tolerated and can be self-administered at home once appropriate training has been provided by a healthcare professional. Needle length is typically short and fine-gauge, but the exact specification varies by device; always follow the instructions provided with your specific device or those given by your healthcare team. Most patients report that, with practice, the process becomes straightforward and causes only mild, brief discomfort.

Subcutaneous injection is not the same as intramuscular injection, which delivers medication deeper into muscle tissue. Injecting into muscle rather than fat can alter the absorption profile of the drug and may increase the risk of pain or bruising.^[8][9] Always follow the technique guidance provided with your medication or by your prescribing clinician to ensure the injection reaches the correct tissue layer.

Choosing the Right Injection Site on Your Body

The abdomen, outer thigh, and outer upper arm are the recommended subcutaneous injection sites; rotating sites at least 1–2 cm apart each week reduces the risk of lipohypertrophy and impaired absorption.

Selecting an appropriate injection site is essential for both comfort and effective drug absorption. For subcutaneous injections, the recommended sites are areas of the body where there is a sufficient layer of subcutaneous fat. The most commonly used sites include:

• Abdomen: The area around the navel, avoiding a 5 cm radius directly around it, is the most frequently recommended site due to its accessibility and consistent fat layer.

• Thighs: The outer, upper thigh is another suitable location, particularly for self-injection.

• Upper arm: The outer aspect of the upper arm can be used, though this site typically requires assistance from another person to ensure accurate subcutaneous (rather than inadvertent intramuscular) placement.

Rotating injection sites is strongly advised. Repeatedly injecting into the same spot can cause local tissue changes, such as injection-site nodules or reactions, and less commonly lipohypertrophy (a localised thickening or hardening of fatty tissue), all of which can impair drug absorption and affect treatment outcomes. A practical rotation approach includes spacing injections at least 1–2 cm apart within the same site and alternating between different sites each week. The FIT UK Injection Technique recommendations provide further evidence-based guidance on site selection and rotation.

Patients should avoid injecting into areas where the skin is broken, bruised, scarred, or affected by skin conditions such as psoriasis or eczema. Areas with visible veins or bony prominences should also be avoided. If you are unsure whether a site is suitable, consult your healthcare provider before proceeding.

Injection Technique: Step-by-Step Guidance

Correct subcutaneous technique involves washing hands, inspecting the device, pinching the skin if advised, inserting the needle at 90 degrees, holding for the specified time, and disposing of sharps safely in an approved container.

Correct injection technique is critical to ensuring the medication is delivered safely and effectively into the subcutaneous fat layer. The following general principles apply to subcutaneous self-injection, but you should always follow the specific instructions provided with your device and by your healthcare team, as details such as hold time, injection speed, and needle length are device-specific.

1. Wash your hands thoroughly with soap and water before handling the injection device.
2. Inspect the medication: Check the solution is clear and colourless, and that the device is undamaged and within its expiry date.
3. Prepare the site: Clean the chosen injection area as directed by your healthcare team or device instructions (an alcohol swab may be recommended in some settings; follow local guidance).
4. Pinch the skin: If advised by your healthcare team or device instructions — particularly if you have less subcutaneous fat or are using a longer needle — gently pinch a fold of skin and subcutaneous tissue between your thumb and forefinger to lift the fat layer away from the muscle beneath.
5. Insert the needle: At a 90-degree angle (or 45 degrees if advised for your body type or device), insert the needle smoothly and fully.
6. Inject and hold: Depress the plunger or activate the pen device steadily, then hold in place for the time specified in your device instructions (often around 10 seconds for pen devices) before withdrawing.
7. Dispose safely: Place the used needle or device immediately into an approved sharps disposal container. In the UK, sharps bins can be obtained from your GP surgery or community pharmacy. Arrange collection or return via your local council's clinical waste service or as directed by your local NHS trust — never dispose of sharps in household waste.

Never recap needles, and do not share devices with others. If you experience persistent difficulty with the technique, ask your diabetes nurse, pharmacist, or GP for a practical demonstration.

Common Injection Site Reactions and When to Seek Help

Mild redness, bruising, and swelling at the injection site are common and usually self-limiting; spreading redness, signs of infection, or allergic reactions require urgent or emergency medical attention.

Injection site reactions are among the most frequently reported adverse effects associated with subcutaneous medicines, including those in the GLP-1 receptor agonist class.^[10][11] Based on data from retatrutide clinical trials (NEJM, 2023) and experience with similar approved agents, patients may experience:

• Redness, swelling, or itching at the injection site, which typically resolves within a few hours to days

• Bruising or mild pain immediately following injection

• Nodules or localised reactions beneath the skin, which may occur with repeated injections at the same site

These reactions are generally mild and self-limiting. Rotating injection sites, as described above, significantly reduces their frequency and severity.

Certain symptoms warrant prompt medical attention. Contact your GP, call NHS 111, or seek urgent care if you notice:

• Significant swelling, warmth, or redness spreading beyond the injection site

• Signs of infection, such as pus, increasing pain, or fever

• A hard, painful lump that does not resolve within a few weeks

• Severe or persistent abdominal pain, with or without vomiting — seek urgent medical assessment, as this may require evaluation for serious conditions such as pancreatitis

• An allergic reaction, including rash, difficulty breathing, or swelling of the face or throat — this requires immediate emergency care (call 999)

Beyond local reactions, retatrutide — like other agents in its class — may cause systemic gastrointestinal side effects such as nausea, vomiting, and diarrhoea, particularly during dose escalation.^[1][2] These should be discussed with your prescribing clinician if they are persistent or significantly affecting your quality of life.

If you experience any suspected side effects from a medicine (including within a clinical trial), you can report these to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. Your report helps improve the safety of medicines for everyone.

Current Status of Retatrutide in the UK

Retatrutide is not approved for clinical use in the UK as of mid-2025; it remains under Phase 3 investigation and has not received MHRA marketing authorisation.

As of mid-2025, retatrutide is not approved for clinical use in the United Kingdom. It remains an investigational compound, developed by Eli Lilly and Company, and is currently undergoing Phase 3 clinical trials evaluating its safety and efficacy in adults with obesity and type 2 diabetes. It has not received a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA). The current trial phase and status can be verified via ClinicalTrials.gov or the EU Clinical Trials Register; readers are encouraged to check these sources for the most up-to-date information, as the development programme is ongoing.

Early-phase results have been promising. Phase 2 data published in the New England Journal of Medicine (2023) demonstrated substantial weight reduction in participants with obesity, with some individuals achieving weight loss exceeding 20% of body weight over 48 weeks. These findings have generated considerable scientific interest; however, Phase 2 results do not guarantee Phase 3 success or regulatory approval.

Patients in the UK who are interested in weight management treatments should speak with their GP or a specialist obesity service. Currently approved options include orlistat, naltrexone/bupropion (Mysimba — note that NHS commissioning of this medicine varies by local area), and semaglutide (Wegovy), which has a NICE technology appraisal recommendation for weight management.^[13] Tirzepatide (Mounjaro) has received MHRA approval and a NICE recommendation primarily for type 2 diabetes; its availability for weight management on the NHS is subject to separate NICE guidance — patients should check the latest NICE publications or speak to their clinician for current eligibility.^[14][15] NICE guidance and local commissioning policies outline BMI thresholds, referral pathways, and duration criteria for these treatments within NHS services.

Patients interested in participating in legitimate clinical research, including trials of investigational medicines such as retatrutide, can search for opportunities via the NIHR's Be Part of Research portal (bepartofresearch.nihs.ac.uk).

It is strongly advised that patients do not attempt to source retatrutide through unregulated online suppliers or grey-market channels. Unapproved medicines obtained outside of licensed clinical trials carry significant safety risks, including unknown purity, incorrect dosing, and absence of medical supervision. Always seek guidance from a registered healthcare professional before starting any new treatment for weight management.

Frequently Asked Questions